Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors

Annovis Bio Inc ((ANVS)) announced an update on their ongoing clinical study.

Annovis Bio Inc. is conducting a clinical trial titled A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer’s Disease. The study aims to evaluate the efficacy and safety of buntanetap/Posiphen in improving cognition and function in adults aged 55-85 with early Alzheimer’s disease. Key objectives include assessing cognitive improvements via ADAS-Cog13 and functional improvements via ADCS-iADL, as well as monitoring any medical issues arising from the treatment.

The intervention being tested is buntanetap/Posiphen, administered as a 30mg capsule taken orally once daily for 18 months. The purpose of this drug is to treat early Alzheimer’s disease by potentially enhancing cognitive and functional abilities in patients.

This interventional study follows a randomized, parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused, aiming to determine the drug’s effectiveness and safety.

The study began on February 4, 2025, with an estimated primary completion date 18 months later. The last update was submitted on July 21, 2025, indicating ongoing recruitment and progress in the trial.

This clinical trial could significantly impact Annovis Bio Inc.’s stock performance and investor sentiment, especially if the results demonstrate positive outcomes. The Alzheimer’s treatment market is highly competitive, with numerous companies vying for breakthroughs, making any advancement in this area potentially lucrative.

The study is currently ongoing, and further details are available on the ClinicalTrials portal.